{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:21Z","timestamp":1786122081435,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Tisagenlecleucel (tis-cel) is the sole chimeric antigen receptor T-cell (CAR-T) therapy approved for pediatric\/adolescent relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL). Infection-related adverse events (IRAEs) represent a leading cause of non-relapse mortality, yet dedicated analysis in patients &lt;18 years remains limited. Objective: This study aimed to analyze the characteristics of IRAEs in pediatric and adolescent patients with r\/r B-ALL treated with tis-cel, based on the FDA Adverse Event Reporting System (FAERS) database. The analysis included the reporting proportion, temporal distribution, pathogen spectrum, and overlapping features with other adverse events, generate hypotheses for infection prevention and control in patients aged &lt;18 years. Research Design and Methods: We analyzed FAERS data (August 2017\u2013March 2025) and included 492 cases of &lt;18-year-old r\/r B-ALL patients treated with tis-cel. Disproportionality analyses (reporting odds ratio, ROR; information component, IC), time-to-onset analysis, and co-occurrence assessments were performed on 149 infection-related reports. Results: Infection-related AEs occurred in 30.28% of cases, with significantly higher mortality in infected versus non-infected patients (40.27% vs. 12.83%, p &lt; 0.001). Most infections (93.86%) occurred within one month (median time-to-onset = 4 days), peaking within 15 days (77.50%); 2.65% occurred after one year. Significant disproportionate reporting signals were observed for Clostridioides difficile (ROR025 = 5.45), influenza virus (ROR025 = 7.16), and adenovirus (ROR025 = 3.51). Hypogammaglobulinemia (52.94%) and hypoxia (54.90%) exhibited higher co-occurrence with infections than CAR-T-specific toxicities (23.08\u201335.41%). Conclusions: Infection-related AEs following tis-cel treatment are frequent and associated with significantly increased mortality in pediatric and adolescent r\/r B-ALL patients. While most occur early, late infections warrant long-term vigilance. Disproportionality analyses identified signals suggestive of potential high-risk pathogens such as Clostridioides difficile,, influenza, and adenovirus, and hypogammaglobulinemia\/hypoxia may serve as early warning indicators. These hypothesis-generating findings require validation in prospective studies.<\/jats:p>","DOI":"10.3390\/children13081054","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:01:36Z","timestamp":1786089696000},"page":"1054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Xiaoxiao","family":"Song","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6731-5566","authenticated-orcid":false,"given":"Xiaohong","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40258-024-00882-4","article-title":"Evolving evidence-based value assessment of one-time therapies: Tisagenlecleucel as a case study","volume":"22","author":"Laetsch","year":"2024","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","volume":"14","author":"Burridge","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_3","first-page":"86","article-title":"Real-world outcomes of commercial Tisagenlecleucel for children, adolescents, and young adults with acute lymphoblastic leukemia in Japan","volume":"31","author":"Kato","year":"2025","journal-title":"Transpl. Cell Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"e70177","article-title":"Inotuzumab ozogamicin as a bridge to stem cell transplantation in relapsed pediatric BCP-ALL after Tisagenlecleucel: A case series","volume":"8","author":"Aertgeerts","year":"2025","journal-title":"Cancer Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lussana, F., Cavallaro, G., De Simone, P., and Rambaldi, A. (2023). Optimal use of novel immunotherapeutics in b-cell precursor ALL. Cancers, 15.","DOI":"10.3390\/cancers15041349"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.46989\/001c.94386","article-title":"The implementation of chimeric antigen receptor (CAR) T-cell therapy in pediatric patients: Where did we come from, where are we now, and where are we going?","volume":"6","author":"Knight","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult b-cell lymphoblastic leukemia after commercial Tisagenlecleucel: A pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: An international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ajh.26246","article-title":"Adverse events reported to the U.S. Food and Drug Administration adverse event reporting system for tisagenlecleucel","volume":"96","author":"Dores","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1182\/blood-2024-209124","article-title":"Comparative analysis of mortality from serious adverse events associated with CAR-t therapies","volume":"144","author":"Cho","year":"2024","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Guo, Z., Ding, Y., Wang, M., Zhai, Q., Liu, J., and Du, Q. (2024). Comparing the differences in adverse events among chimeric antigen receptor t-cell therapies: A real-world pharmacovigilance study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081025"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yu, X., Zhong, J., Zhuang, X., Lin, Z., Fu, H., and Zhang, Y. (2025). Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: A real-world retrospective and pharmacovigilance study. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1533902"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.clinthera.2025.05.004","article-title":"Calcineurin inhibitors and risk of CNS infections: A disproportionality analysis of the FDA adverse event reporting system (FAERS)","volume":"47","author":"Ning","year":"2025","journal-title":"Clin. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, G., Su, L., Liu, Y., Yang, X., Li, Y., Mei, Q., and Gao, W. (2025). Cardiovascular toxicity of tisagenlecleucel in children and adolescents: Analysis of spontaneous reports submitted to FAERS. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1499143"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: Data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Mantadakis, E., Stiakaki, E., Groll, A.H., and Tragiannidis, A. (2022). Infectious complications of targeted therapies in children with leukemias and lymphomas. Cancers, 14.","DOI":"10.3390\/cancers14205022"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with b cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40273-019-00799-0","article-title":"Tisagenlecleucel for the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years: An evidence review group perspective of a NICE single technology appraisal","volume":"37","author":"Walton","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Arya, S., and Shahid, Z. (2024). Overview of infectious complications among CAR t- cell therapy recipients. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1398078"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: A large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) t-cell therapy: Characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","first-page":"2430","article-title":"How i treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_28","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory b-cell acute lymphoblastic leukemia treated with chimeric antigen receptor t cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified t cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large b cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2023062307","DOI":"10.1542\/peds.2023-062307","article-title":"Clostridioides difficile infection in children: Recent updates on epidemiology, diagnosis, therapy","volume":"152","author":"Shirley","year":"2023","journal-title":"Pediatrics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/INF.0000000000003117","article-title":"Changes in Metronidazole and Vancomycin utilization for nonsevere Clostridioides difficile infection among institutions caring for children","volume":"40","author":"Stultz","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor t (CAR-t) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10238-024-01339-7","article-title":"Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed\/refractory B-lymphoblastic leukemia","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_38","first-page":"3557","article-title":"Management of complications of chimeric antigen receptor T-cell therapy: A report by the european society of blood and marrow transplantation","volume":"109","author":"Penack","year":"2024","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-t - and a side order of IgG, to go? - immunoglobulin replacement in patients receiving CAR-t cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e26914","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: A position paper","volume":"49","author":"Iacoboni","year":"2021","journal-title":"Infection"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Garner, W., Samanta, P., and Haidar, G. (2021). Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified t-cell therapy: State of the evidence and future directions. J. Fungi, 7.","DOI":"10.3390\/jof7020156"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/8\/1054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:31:42Z","timestamp":1786091502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/8\/1054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["children13081054"],"URL":"https:\/\/doi.org\/10.3390\/children13081054","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}